Molecular interactions between zoledronic acid and bone: An in vitro Raman microspectroscopic study

Bone

Volumn 47, Issue 5, 2010, Pages 895-904

  Juillard, Audrey ^a,b   Falgayrac, Guillaume ^a,b   Cortet, Bernard ^a,b   Vieillard, Marie Hélène ^a,b   Azaroual, Nathalie ^a   Hornez, Jean Christophe ^a,c   Penel, Guillaume ^a,b  

^a UNIV LILLE   (France)

^b Physiopathologie des Maladies Osseuses Inflammatoires   (France)

^c UNIVERSITÉ DE VALENCIENNES   (France)

Author keywords

Bone; Hydroxyapatite; Molecular interactions; Raman microspectroscopy; Zoledronic acid

Indexed keywords

CARBONIC ACID; HYDROXYAPATITE; IMIDAZOLE; MINERAL; PHOSPHATE; ZOLEDRONIC ACID;

ANIMAL TISSUE; ARTICLE; BONE MINERAL; BONE STRENGTH; BONE TISSUE; CONTROLLED STUDY; DRUG BINDING; FEMUR; IN VITRO STUDY; MALE; MOLECULAR INTERACTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSICAL CHEMISTRY; RAMAN SPECTROMETRY; RAT; SCANNING ELECTRON MICROSCOPY;

ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMUR; IMIDAZOLES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PHOSPHATES; RATS; RATS, WISTAR; SPECTRUM ANALYSIS, RAMAN;

EID: 77957751749     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.07.018     Document Type: Article

References (48)

1. Green J.R. Bisphosphonates: preclinical review. Oncologist 2004, 9:3-13.
2. Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002, 62:6538-6544.
3. Wood J., Bonjean K., Ruetz S., Bellahcene A., Devy L., Foidart J.M., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302:1055-1061.
4. Rosen L.S., Gordon D.H., Dugan W.J., Major P., Eisenberg P.D., Provencher L., et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004, 100:36-43.
5. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
6. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998, 19:80-100.
7. van Beek E.R., Löwik C.W.G.M., Ebetino F.H., Papapoulos S.E. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone 1998, 23:437.
8. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38:617.
9. Russell R., Watts N., Ebetino F., Rogers M. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis International 2008, 19:733.
10. Josse S., Faucheux C., Soueidan A., Grimandi G., Massiot D., Alonso B., et al. Novel biomaterials for bisphosphonate delivery. Biomaterials 2005, 26:2073.
11. Mukherjee S., Song Y., Oldfield E. NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model. J Am Chem Soc 2008, 130:1264-1273.
12. Bohic S., Rey C., Legrand A., Sfihi H., Rohanizadeh R., Martel C., et al. Characterization of the trabecular rat bone mineral: effect of ovariectomy and bisphosphonate treatment. Bone 2000, 26:341.
13. Burr D.B., Miller L., Grynpas M., Li J., Boyde A., Mashiba T., et al. Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone 2003, 33:960.
14. Camacho N.P., Carroll P., Raggio C.L. Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice. Calcif Tissue Int 2003, 72:604.
15. Durchschlag E., Paschalis E.P., Zoehrer R., Roschger P., Fratzl P., Recker R., et al. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res 2006, 21:1581-1590.
16. Ammann P. Bone strength and ultrastructure. Osteoporos Int 2009, 20:1081.
17. Fratzl P., Roschger P., Fratzl-Zelman N., Paschalis E., Phipps R., Klaushofer K. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. Calcif Tissue Int 2007, 81:73.
18. Laurent Benhamou C. Bone ultrastructure: evolution during osteoporosis and aging. Osteoporos Int 2009, 20:1085.
19. Turner C.H. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 2002, 13:97.
20. Carden A., Morris M.D. Application of vibrational spectroscopy to the study of mineralized tissues (review). J Biomed Opt 2000, 5:259.
21. McCreadie B.R., Morris M.D., Chen T.-c., Sudhaker Rao D., Finney W.F., Widjaja E., et al. Bone tissue compositional differences in women with and without osteoporotic fracture. Bone 2006, 39:1190.
22. Wasserman N., Yerramshetty J., Akkus O. Microcracks colocalize within highly mineralized regions of cortical bone tissue. Eur J Morphol 2005, 42:43-51.
23. Lakshmi R.J., Alexander M., Kurien J., Mahato K.K., Kartha V.B. Osteoradionecrosis (ORN) of the mandible: a laser Raman Spectroscopic Study. Applied Spectroscopy 2003, 1100.
24. Yerramshetty J.S., Lind C., Akkus O. The compositional and physicochemical homogeneity of male femoral cortex increases after the sixth decade. Bone 2006, 39:1236.
25. Hornez J.C., Chai F., Monchau F., Blanchemain N., Descamps M., Hildebrand H.F. Biological and physico-chemical assessment of hydroxyapatite (HA) with different porosity. Biomol Eng 2007, 24:505.
26. Jaumot J., Gargallo R., de Juan A., Tauler R. A graphical user-friendly interface for MCR-ALS: a new tool for multivariate curve resolution in MATLAB. Chemom Intell Lab Syst 2005, 76:101.
27. Windig W., Antalek B., Lippert J.L., Batonneau Y., Bremard C. Combined use of conventional and second-derivative data in the SIMPLISMA self-modeling mixture analysis approach. Anal Chem 2002, 74:1371.
28. Falgayrac G., Sobanska S., Laureyns J., Brémard C. Heterogeneous chemistry between PbSO4 and calcite microparticles using Raman microimaging. Spectrochim Acta A Mol Biomol Spectrosc 2006, 64:1095.
29. Windig W., Gallagher N.B., Shaver J.M., Wise B.M. A new approach for interactive self-modeling mixture analysis. Chemom Intell Lab Syst 2005, 77:85.
30. Shen J., Fan L., Yang J., Shen A.G., Hu J.M. A longitudinal Raman microspectroscopic study of osteoporosis induced by spinal cord injury. Osteoporos Int 2010, 21:81-87.
31. Donnelly E., Boskey A.L., Baker S.P., van der Meulen M.C.H. Effects of tissue age on bone tissue material composition and nanomechanical properties in the rat cortex. J Biomed Mater Res A 2009, 92:1048-1056.
32. Gourion-Arsiquaud S., Burket J.C., Havill L.M., DiCarlo E., Doty S.B., Mendelsohn R., et al. Spatial variation in osteonal bone properties relative to tissue and animal age. J Bone Miner Res 2009, 24:1271-1281.
33. Penel G., Leroy G., Rey C., Bres E. MicroRaman Spectral Study of the PO4 and CO3 vibrational modes in synthetic and biological apatites. Calcif Tissue Int 1998, 63:475.
34. Falgayrac G, Facq S, Leroy G, Cortet B, Penel G. A new method for Raman investigation of collagen fibrils and crystallites orientation in bone Haversian's system. Appl Spectrosc in press;64.
35. Gamsjaeger S., Masic A., Roschger P., Kazanci M., Dunlop J.W.C., Klaushofer K., Paschalis E.P., Fratzl P. Cortical bone composition and orientation as a function of animal and tissue age in mice by Raman spectroscopy. Bone 2010, 47(2):392-399.
36. Cukrowski I., Popovic L., Barnard W., Paul S.O., van Rooyen P.H., Liles D.C. Modeling and spectroscopic studies of bisphosphonate-bone interactions. The Raman, NMR and crystallographic investigations of Ca-HEDP complexes. Bone 2007, 41:668.
37. James C., Ravikumar C., Jayakumar V.S., Hubert J.I. Vibrational spectra and potential energy distributions for 1-benzyl-1H-imidazole by normal coordinate analysis. J Raman Spectrosc 2009, 40:537-545.
38. Jarzecki A.A., Spiro T.G. Ab initio computation of the UV resonance Raman intensity pattern of aqueous imidazole. J Raman Spectrosc 2001, 32:599-605.
39. Loo B.H., Tse Y., Parsons K., Adelman C., El-Hage A., Lee Y.G. Surface-enhanced Raman spectroscopy of imidazole adsorbed on electrode and colloidal surfaces of Cu, Ag, and Au. J Raman Spectrosc 2006, 37:299-304.
40. Elliot J.C. Structure and chemistry of the apatites and other calcium orthophosphates 1994, Elsevier Science B.V., Amsterdam.
41. Redman-Furey N., Dicks M., Bigalow-Kern A., Cambron R.T., Lubey G., Lester C., et al. Structural and analytical characterization of three hydrates and an anhydrate form of risedronate. J Pharm Sci 2005, 94:893-911.
42. Rey C., Combes C., Drouet C., Glimcher M. Bone mineral: update on chemical composition and structure. Osteoporos Int 2009, 20:1013.
43. Mukherjee S., Huang C., Guerra F., Wang K., Oldfield E. Thermodynamics of bisphosphonates binding to human bone: a two-site model. J Am Chem Soc 2009, 131:8374.
44. Leventouri T. Synthetic and biological hydroxyapatites: crystal structure questions. Biomaterials 2006, 27:3339.
45. Nelson D.G.A. The influence of carbonate on the atomic structure and reactivity of hydroxyapatite. J Dent Res 1981, 60:1621.
46. Zapanta-Legeros R. Effect of carbonate on the lattice parameters of apatite. Nature 1965, 206:403.
47. Yao F., LeGeros J.P., LeGeros R.Z. Simultaneous incorporation of carbonate and fluoride in synthetic apatites: effect on crystallographic and physico-chemical properties. Acta Biomater 2009, 5:2169.
48. Antonakos A., Liarokapis E., Leventouri T. Micro-Raman and FTIR studies of synthetic and natural apatites. Biomaterials 2007, 28:3043.